title: A case of an SLE patient with febrile neutropenia who experienced exacerbation of cutaneous manifestations after the administration of G-CSF.
abstract: Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease. Although hematological anomalies are commonly found in SLE, severe polymorphonuclear leukocyte depletion is rare. Most episodes of severe granulocytopenia in SLE patients tend to occur as part of drug toxicity-induced medullar hypoplasia, and recombinant human (rh) granulocyte colony-stimulating factor (G-CSF) has been shown to be effective for treating neutropenia associated with SLE. However, flares of some autoimmune diseases, including flares in six SLE patients, have been reported after G-CSF therapy. This report presents the case of a patient with SLE who experienced exacerbation of skin symptoms after G-CSF therapy. There is sufficient evidence to suggest that G-CSF can exacerbate inflammatory disease. Furthermore, the possibility that several factors other than rhG-CSF may affect the disease activity of SLE should be considered when SLE patients with neutropenia require the administration of rhG-CSF. Therefore rhG-CSF should be used with considerable caution in neutropenic patients with SLE.
authors.affiliation: Department of Dermatology, Faculty of Medicine, University of Oita, 1-1 Idaigaoka, Hasama-machi, Yufu, Oita, 879-5593, Japan, t-sakai@oita-u.ac.jp.
authors.forename: Takashi
authors.initials: T
authors.lastname: Sakai
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Hatano
authors.forename: Itomi
authors.initials: I
authors.lastname: Abe
authors.forename: Koji
authors.initials: K
authors.lastname: Ishii
authors.forename: Sakuhei
authors.initials: S
authors.lastname: Fujiwara
mesh_terms: D000293:Adolescent; D004890:Erythema / Q000139:chemically induced*; D064147:Febrile Neutropenia / Q000150:complications / Q000188:drug therapy*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy*; D012867:Skin / Q000187:drug effects* / Q000473:pathology
chemical_list: D016179:Granulocyte Colony-Stimulating Factor